MedKoo Cat#: 413478 | Name: Dasotraline Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dasotraline Free Base inhibits both dopamine and norepinephrine transporters and is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Chemical Structure

Dasotraline Free Base
Dasotraline Free Base
CAS#675126-05-3 (free base)

Theoretical Analysis

MedKoo Cat#: 413478

Name: Dasotraline Free Base

CAS#: 675126-05-3 (free base)

Chemical Formula: C16H15Cl2N

Exact Mass: 291.0582

Molecular Weight: 292.20

Elemental Analysis: C, 65.77; H, 5.17; Cl, 24.26; N, 4.79

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Dasotraline Free Base; SEP 225289; SEP225289; SEP-225289
IUPAC/Chemical Name
(1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
InChi Key
SRPXSILJHWNFMK-MEDUHNTESA-N
InChi Code
InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
SMILES Code
N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C3=C1C=CC=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
To be determined 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 292.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Vandana P, Arnold E. Dasotraline in ADHD: novel or me too drug? Expert Rev Neurother. 2019 Apr;19(4):311-315. doi: 10.1080/14737175.2019.1593826. Epub 2019 Mar 26. PMID: 30871381. 2: Findling RL, Adler LA, Spencer TJ, Goldman R, Hopkins SC, Koblan KS, Kent J, Hsu J, Loebel A. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):80-89. doi: 10.1089/cap.2018.0083. Epub 2019 Jan 29. PMID: 30694697. 3: Yang X, Ryu S, Di L. Dasotraline as a selective cytochrome 2B6 inhibitor for reaction phenotyping. Biopharm Drug Dispos. 2019 Nov;40(9):358-361. doi: 10.1002/bdd.2207. PMID: 31674039. 4: Wigal SB, Hopkins SC, Koblan KS, Childress A, Kent JM, Tsai J, Hsu J, Loebel A, Goldman R. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. J Atten Disord. 2020 Jan;24(2):192-204. doi: 10.1177/1087054719864644. Epub 2019 Aug 2. PMID: 31375051. 5: Grilo CM, McElroy SL, Hudson JI, Tsai J, Navia B, Goldman R, Deng L, Kent J, Loebel A. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. CNS Spectr. 2020 May 19:1-10. doi: 10.1017/S1092852920001406. Epub ahead of print. PMID: 32423512. 6: McElroy SL, Hudson JI, Grilo CM, Guerdjikova AI, Deng L, Koblan KS, Goldman R, Navia B, Hopkins S, Loebel A. Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial. J Clin Psychiatry. 2020 Sep 8;81(5):19m13068. doi: 10.4088/JCP.19m13068. PMID: 32926604. 7: Mosholder AD, Kim J, Davis M, Farchione TR. Re: "Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed- Dose Trial" by Findling et al. (J Child Adolesc Psychopharmacol 2019;29:80-89). J Child Adolesc Psychopharmacol. 2019 Nov;29(9):725. doi: 10.1089/cap.2019.0061. Epub 2019 May 16. PMID: 31094581. 8: Lew R, Constantinescu CC, Holden D, Carson RE, Carroll V, Galluppi G, Koblan KS, Hopkins SC. The rate of dasotraline brain entry is slow following intravenous administration. Psychopharmacology (Berl). 2020 Nov;237(11):3435-3446. doi: 10.1007/s00213-020-05623-8. Epub 2020 Aug 19. PMID: 32813030; PMCID: PMC7651685. 9: Citrome L. Binge eating disorder revisited: what's new, what's different, what's next. CNS Spectr. 2019 Aug;24(S1):4-13. doi: 10.1017/S1092852919001032. Erratum in: CNS Spectr. 2019 Aug;24(S1):82. PMID: 31196238. 10: Appolinario JC, Nardi AE, McElroy SL. Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Investig Drugs. 2019 Dec;28(12):1081-1094. doi: 10.1080/13543784.2019.1692813. Epub 2019 Nov 22. PMID: 31714807.